Your browser version may not work well with NCBI's Web applications. More information here...
1: Aliment Pharmacol Ther. 2008 Dec 1;28(11-12):1317-25. Epub 2008 Aug 4.
Related Articles, Links
Click here to read Click here to read
Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase.

Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, Tully O, Kearney K, Lazowick D, Mercogliano G, Thornton JJ.

The Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA. mulllinj@mlhs.org

BACKGROUND: Proton pump inhibitors (PPIs) are one of the most widely used drug classes in the US and are now frontline medications for gastro-oesophageal reflux disease (GERD) and dyspepsia. In a previous work, we observed that a transmucosal, upper gastrointestinal (GI) leak exists in Barrett's oesophagus (BO) patients. PPI medications are commonly used by Barrett's patients. AIM: To examine if the PPI, esomeprazole, affects the barrier function of the upper GI tract. METHODS: The sucrose permeability test (SPT) was used to assess the possible effect of the PPI, esomeprazole, on upper GI leak in 37 first-time-presenting GERD patients and 25 healthy controls. RESULTS: Esomeprazole induced a significant transmucosal leak in the upper GI tract of patients taking the drug for the first time. The leak occurred quickly, within days of first taking the drug. The leak was also reversed within days of stopping the medication. CONCLUSIONS: This is the first patient-based study showing that a PPI compromises upper GI barrier function. There are potential implications for transmucosal leak of other medications that a patient on a PPI may be taking, as well as possible leak of endogenous peptides/proteins. The clinical consequences of this phenomenon are currently unknown, but are potentially important.

Publication Types:
PMID: 18684245 [PubMed - in process]